Zolbetuximab
Zolbetuximab Basic information
- Product Name:
- Zolbetuximab
- Synonyms:
-
- Zolbetuximab
- Research Grade Zolbetuximab (DHF19801)
- Zolbetuximab (IMAB362)
- Research Grade Zolbetuximab
- IMAB362
- Zolbetuximab (anti-CLDN18.2)
- CAS:
- 1496553-00-4
- MW:
- 0
- Mol File:
- Mol File
Zolbetuximab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Zolbetuximab Usage And Synthesis
Uses
Zolbetuximab (development code IMAB362) is an experimental monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors.
Mechanism of action
Zolbetuximab is the first drug developed against the target of Claudin18.2. It is a chimeric IgG1 monoclonal antibody that specifically binds to Claudin18.2 on the surface of tumor cells, thereby triggering antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), apoptosis and inhibition of cell proliferation.
in vivo
Zolbetuximab (200 μg, i.v.) alone and in combination with Gemcitabine (HY-17026) (50 mg/kg, i.p.) exhibits antitumor activity in mouse BxPC-3-CLDN18.2 xenograft models[2].
Zolbetuximab (5.7 mg/kg, i.p., three times per week for five weeks) inhibits tumor growth in SNU-620 cells xenograft model[3].
| Animal Model: | mouse BxPC-3-CLDN18.2, MIA PaCa-2-CLDN18.2 xenograft model[2] |
| Dosage: | 200 μg alone or with 50 mg/kg Gemcitabine |
| Administration: | i.v.; i.p. (Gemcitabine) |
| Result: | Inhibited tumor growth in two models, and prevented lung metastasis formation. Prolonged survival time, and lowered fractions of CLDN18.2+ cells in MIA PaCa-2-CLDN18.2 xenograft. |
ZolbetuximabSupplier
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 15817493340
- 981810490@qq.com